Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo.
The treatment of symptomatic chronic obstructive peripheral arteriopathies is a difficult task since it requires the prolonged administration of drugs which are often unable to correct the various pathogenetic factors reponsible for the disability. The authors, on the basis of recent studies demonstrating the rheological and vasoactive as well as metabolic activities of levocarnitine propionyl, have decided to use this substance in the treatment of arteriopathics affected by intermittent claudication. Levocarnitine propionyl administered orally to 142 arteriopathics affected by intermittent claudication was responsible for a marked increase in initial as well as absolute walking distances. It is particularly important to note that these clinical results were obtained primarily due to the metabolic activities of levocarnitine propionyl.
Coto
V
V
IV Internal Medicine Department, II Medical School, University of Naples, Italy.
D'Alessandro
L
L
Grattarola
G
G
Imparato
L
L
Lingetti
M
M
Mancini
M
M
Nolfe
G
G
Rengo
F
F
D000284:Administration, Oral; D000368:Aged; D000704:Analysis of Variance; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001161:Arteriosclerosis / Q000188:drug therapy; D002331:Carnitine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000188:drug therapy; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012044:Regression Analysis; D013237:Stereoisomerism
C003223:propionylcarnitine; D002331:Carnitine